CorMedix (NASDAQ:CRMD) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CorMedix (NASDAQ:CRMD - Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

Several other research analysts have also issued reports on CRMD. StockNews.com upgraded shares of CorMedix to a "sell" rating in a research report on Friday, November 8th. Royal Bank of Canada upped their target price on shares of CorMedix from $11.00 to $12.00 and gave the stock an "outperform" rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.00.

CorMedix Trading Up 12.9 %

Shares of CRMD traded up $1.22 during mid-day trading on Wednesday, reaching $10.71. 1,575,899 shares of the stock traded hands, compared to its average volume of 1,093,270. CorMedix has a 1 year low of $3.03 and a 1 year high of $13.85. The company has a market cap of $649.85 million, a price-to-earnings ratio of -13.22 and a beta of 1.53. The firm has a fifty day moving average price of $10.54 and a 200 day moving average price of $9.51.

Remove Ads

Institutional Trading of CorMedix

Several institutional investors have recently added to or reduced their stakes in the business. Palisades Investment Partners LLC purchased a new stake in shares of CorMedix during the fourth quarter worth about $2,949,000. Two Sigma Investments LP boosted its holdings in shares of CorMedix by 19.7% during the fourth quarter. Two Sigma Investments LP now owns 31,489 shares of the company's stock worth $255,000 after purchasing an additional 5,189 shares during the period. Rafferty Asset Management LLC purchased a new stake in shares of CorMedix during the fourth quarter worth about $120,000. ProShare Advisors LLC boosted its holdings in shares of CorMedix by 92.2% during the fourth quarter. ProShare Advisors LLC now owns 19,947 shares of the company's stock worth $162,000 after purchasing an additional 9,568 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of CorMedix by 1.0% during the fourth quarter. Nuveen Asset Management LLC now owns 171,978 shares of the company's stock worth $1,393,000 after purchasing an additional 1,679 shares during the period. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.